Circulating Tumor Cell-Derived Organoids: Current Progress, Applications, and Future

Abstract

Circulating tumor cells (CTCs) are malignant cells that detach from primary or metastatic tumors and enter the bloodstream. Organoids, as three-dimensional in vitro models, can mimic the tumor microenvironment and histopathological characteristics, thereby serving as valuable tools in tumor research. CTC-derived organoids retain tumor heterogeneity and metastatic potential, which provides a unique model for the study of metastatic cascade mechanisms, individualized drug screening, and precision therapy. However, the current research on CTC-derived organoids faces challenges, such as the scarcity of CTCs and the high technical difficulty in their isolation and enrichment, which leads to a low success rate in constructing organoid models. Moreover, most existing studies focus on a single cancer type and lack systematic integration of full-process standardization as well as cross-cancer applicability. In this paper, we review the isolation and enrichment strategies of CTC-derived organoids along with the techniques for optimizing in vitro culture systems, and discusses their potential applications. This review summarizes the existing results, analyzes the technical bottlenecks, and provides a theoretical basis for the standardized construction and application of CTC-derived organoids, while promoting their application in tumor precision medicine.

Keywords

cancer / circulating tumor cells / organoids / precision medicine

References

[1] M. Nikanjam, S. Kato, and R. Kurzrock, “Liquid Biopsy: Current Technology and Clinical Applications,” Journal of Hematology & Oncology 15, no. 1 (2022): 131.

[2] Z. Ding, N. Wang, N. Ji, and Z. S. Chen, “Proteomics Technologies for Cancer Liquid Biopsies,” Molecular Cancer 21, no. 1 (2022): 53.

[3] S. Zhou, H. Xu, Y. Duan, Q. Tang, H. Huang, and F. Bi, “Survival Mechanisms of Circulating Tumor Cells and Their Implications for Cancer Treatment,” Cancer and Metastasis Reviews 43, no. 3 (2024): 941–957.

[4] S. Gkountela, F. Castro-Giner, B. M. Szczerba, et al., “Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding,” Cell 176, no. 1–2 (2019): 98–112.e14.

[5] Y. Zhang, C. Wang, W. Li, et al., “Neutrophil Cyto-Pharmaceuticals Suppressing Tumor Metastasis via Inhibiting Hypoxia-Inducible Factor-1α in Circulating Breast Cancer Cells,” Advanced Healthcare Materials 11, no. 3 (2022): e2101761.

[6] B. M. Szczerba, F. Castro-Giner, M. Vetter, et al., “Neutrophils Escort Circulating Tumour Cells to Enable Cell Cycle Progression,” Nature 566, no. 7745 (2019): 553–557.

[7] W. S. Tsai, J. F. You, H. Y. Hung, et al., “Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer,” Clinical and Translational Gastroenterology 10, no. 10 (2019): e00088.

[8] Y. Li, X. Cheng, Z. Chen, Y. Liu, Z. Liu, and S. Xu, “Circulating Tumor Cells in Peripheral and Pulmonary Venous Blood Predict Poor Long-Term Survival in Resected Non-Small Cell Lung Cancer Patients,” Scientific Reports 7, no. 1 (2017): 4971.

[9] R. Lawrence, M. Watters, C. R. Davies, K. Pantel, and Y. J. Lu, “Circulating Tumour Cells for Early Detection of Clinically Relevant Cancer,” Nature Reviews Clinical Oncology 20, no. 7 (2023): 487–500.

[10] A. Szczepanik, M. Sierzega, G. Drabik, A. Pituch-Noworolska, P. Kołodziejczyk, and M. Zembala, “CD44(+) Cytokeratin-Positive Tumor Cells in Blood and Bone Marrow Are Associated With Poor Prognosis of Patients With Gastric Cancer,” Gastric Cancer 22, no. 2 (2019): 264–272.

[11] F. C. Bidard, W. Jacot, N. Kiavue, et al., “Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-Line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial,” JAMA Oncology 7, no. 1 (2021): 34–41.

[12] D. Lin, L. Shen, M. Luo, et al., “Circulating Tumor Cells: Biology and Clinical Significance,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 404.

[13] Y. Ishiguro, H. Sakihama, T. Yoshida, et al., “Prognostic Significance of Circulating Tumor Cells With Mesenchymal Phenotypes in Patients With Gastric Cancer: A Prospective Study,” Annals of Surgical Oncology 28, no. 2 (2021): 1178–1186.

[14] A. Satelli, I. S. Batth, Z. Brownlee, et al., “Potential Role of Nuclear PD-L1 Expression in Cell-Surface Vimentin Positive Circulating Tumor Cells as a Prognostic Marker in Cancer Patients,” Scientific Reports 6 (2016): 28910.

[15] S. Yang, H. Hu, H. Kung, et al., “Organoids: The Current Status and Biomedical Applications,” MedComm 4, no. 3 (2023): e274.

[16] S. Qu, R. Xu, G. Yi, et al., “Patient-Derived Organoids in Human Cancer: A Platform for Fundamental Research and Precision Medicine,” Molecular Biomedicine 5, no. 1 (2024): 6.

[17] K. Yuki, N. Cheng, M. Nakano, and C. J. Kuo, “Organoid Models of Tumor Immunology,” Trends in Immunology 41, no. 8 (2020): 652–664.

[18] R. Xu, X. Zhou, S. Wang, and C. Trinkle, “Tumor Organoid Models in Precision Medicine and Investigating Cancer-Stromal Interactions,” Pharmacology & Therapeutics 218 (2021): 107668.

[19] Y. Hu, T. Zhu, H. Cui, and H. Cui, “Integrating 3D Bioprinting and Organoids to Better Recapitulate the Complexity of Cellular Microenvironments for Tissue Engineering,” Advanced Healthcare Materials 14, no. 3 (2025): e2403762.

[20] T. Zhu, Y. Hu, H. Cui, and H. Cui, “3D Multispheroid Assembly Strategies Towards Tissue Engineering and Disease Modeling,” Advanced Healthcare Materials 13, no. 23 (2024): e2400957.

[21] M. M. A. Verstegen, R. P. Coppes, A. Beghin, et al., “Clinical Applications of Human Organoids,” Nature Medicine 31, no. 2 (2025): 409–421.

[22] C. Pan, X. Wang, C. Yang, K. Fu, F. Wang, and L. Fu, “The Culture and Application of Circulating Tumor Cell-Derived Organoids,” Trends in Cell Biology 35, no. 5 (2025): 364–380.

[23] M. S. Tretyakova, M. E. Menyailo, A. A. Schegoleva, U. A. Bokova, I. V. Larionova, and E. V. Denisov, “Technologies for Viable Circulating Tumor Cell Isolation,” International Journal of Molecular Sciences 23, no. 24 (2022): 15979.

[24] C. Wei, C. Yang, S. Wang, et al., “Crosstalk Between Cancer Cells and Tumor Associated Macrophages Is Required for Mesenchymal Circulating Tumor Cell-Mediated Colorectal Cancer Metastasis,” Molecular Cancer 18, no. 1 (2019): 64.

[25] Z. Deng, S. Wu, Y. Wang, and D. Shi, “Circulating Tumor Cell Isolation for Cancer Diagnosis and Prognosis,” EBioMedicine 83 (2022): 104237.

[26] Q. Zhan, B. Liu, X. Situ, et al., “New Insights Into the Correlations Between Circulating Tumor Cells and Target Organ Metastasis,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 465.

[27] Z. Huang, Z. Zhang, C. Zhou, L. Liu, and C. Huang, “Epithelial-Mesenchymal Transition: The History, Regulatory Mechanism, and Cancer Therapeutic Opportunities,” MedComm 3, no. 2 (2022): e144.

[28] B. Bakir, A. M. Chiarella, J. R. Pitarresi, and A. K. Rustgi, “EMT, MET, Plasticity, and Tumor Metastasis,” Trends in Cell Biology 30, no. 10 (2020): 764–776.

[29] S. Orrapin, S. Udomruk, W. Lapisatepun, et al., “Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review,” Cancers 14, no. 14 (2022): 3373.

[30] S. Brabletz, H. Schuhwerk, T. Brabletz, and M. P. Stemmler, “Dynamic EMT: A Multi-Tool for Tumor Progression,” EMBO Journal 40, no. 18 (2021): e108647.

[31] M. Saini, L. Schmidleitner, H. D. Moreno, et al., “Resistance to Mesenchymal Reprogramming Sustains Clonal Propagation in Metastatic Breast Cancer,” Cell Reports 42, no. 6 (2023): 112533.

[32] J. Xiong, Q. Sun, K. Ji, Y. Wang, and H. Liu, “Epidermal Growth Factor Promotes Transforming Growth Factor-β1-Induced Epithelial-Mesenchymal Transition in HK-2 Cells Through a Synergistic Effect on Snail,” Molecular Biology Reports 41, no. 1 (2014): 241–250.

[33] T. Pereira-Veiga, S. Schneegans, K. Pantel, and H. Wikman, “Circulating Tumor Cell-Blood Cell Crosstalk: Biology and Clinical Relevance,” Cell Reports 40, no. 9 (2022): 111298.

[34] J. Park, S. Park, K. A. Hyun, and H. I. Jung, “Microfluidic Recapitulation of Circulating Tumor Cell-Neutrophil Clusters via Double Spiral Channel-Induced Deterministic Encapsulation,” Lab on a Chip 21, no. 18 (2021): 3483–3497.

[35] M. D. Filippi, “Neutrophil Transendothelial Migration: Updates and New Perspectives,” Blood 133, no. 20 (2019): 2149–2158.

[36] S. Najmeh, J. Cools-Lartigue, R. F. Rayes, et al., “Neutrophil Extracellular Traps Sequester Circulating Tumor Cells via β1-Integrin Mediated Interactions,” International Journal of Cancer 140, no. 10 (2017): 2321–2330.

[37] J. D. Spicer, B. McDonald, J. J. Cools-Lartigue, et al., “Neutrophils Promote Liver Metastasis via Mac-1-Mediated Interactions With Circulating Tumor Cells,” Cancer Research 72, no. 16 (2012): 3919–3927.

[38] M. Mohme, S. Riethdorf, and K. Pantel, “Circulating and Disseminated Tumour Cells-Mechanisms of Immune Surveillance and Escape,” Nature Reviews Clinical Oncology 14, no. 3 (2017): 155–167.

[39] Z. J. Que, J. L. Yao, Z. Y. Zhou, et al., “Jinfukang Inhibits Lung Cancer Metastasis by Upregulating CX3CL1 to Recruit NK Cells to Kill CTCs,” Journal of Ethnopharmacology 275 (2021): 114175.

[40] P. Hofman, S. Heeke, C. Alix-Panabières, and K. Pantel, “Liquid Biopsy in the Era of Immuno-Oncology: Is It Ready for Prime-Time Use for Cancer Patients?,” Annals of Oncology 30, no. 9 (2019): 1448–1459.

[41] Y. Ward, R. Lake, F. Faraji, et al., “Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling That Coordinates Transendothelial Migration,” Cell Reports 23, no. 3 (2018): 808–822.

[42] S. Lorenzo-Herrero, A. López-Soto, C. Sordo-Bahamonde, A. P. Gonzalez-Rodriguez, M. Vitale, and S. Gonzalez, “NK Cell-Based Immunotherapy in Cancer Metastasis,” Cancers 11, no. 1 (2018): 29.

[43] A. L. Palacios-Acedo, D. Mège, L. Crescence, F. Dignat-George, C. Dubois, and L. Panicot-Dubois, “Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy,” Frontiers in immunology 10 (2019): 1805.

[44] R. Helwa, A. Heller, S. Knappskog, and A. S. Bauer, “Tumor Cells Interact With Red Blood Cells via galectin-4—A Short Report,” Cellular Oncology 40, no. 4 (2017): 401–409.

[45] A. Ring, B. D. Nguyen-Sträuli, A. Wicki, and N. Aceto, “Biology, Vulnerabilities and Clinical Applications of Circulating Tumour Cells,” Nature Reviews Cancer 23, no. 2 (2023): 95–111.

[46] J. Kapeleris, H. Zou, Y. Qi, et al., “Cancer Stemness Contributes to Cluster Formation of Colon Cancer Cells and High Metastatic Potentials,” Clinical and experimental pharmacology & physiology 47, no. 5 (2020): 838–847.

[47] M. Yu, “Metastasis Stemming From Circulating Tumor Cell Clusters,” Trends in Cell Biology 29, no. 4 (2019): 275–276.

[48] N. K. Dashzeveg, Y. Jia, Y. Zhang, et al., “Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer,” Cancer Discovery 13, no. 9 (2023): 2050–2071.

[49] B. M. Mohamed, M. P. Ward, M. Bates, et al., “Ex Vivo Expansion of Circulating Tumour Cells (CTCs),” Scientific Reports 13, no. 1 (2023): 3704.

[50] N. Aceto, A. Bardia, D. T. Miyamoto, et al., “Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis,” Cell 158, no. 5 (2014): 1110–1122.

[51] S. Guo, J. Huang, G. Li, W. Chen, Z. Li, and J. Lei, “The Role of Extracellular Vesicles in Circulating Tumor Cell-Mediated Distant Metastasis,” Molecular Cancer 22, no. 1 (2023): 193.

[52] T. Cheytan, M. Schneider, R. Würth, et al., “Small Extracellular Vesicles and Particles (sEVPs) Derived From Tumor-Free Pre-Metastatic Organs Promote Breast Cancer Metastasis and Support Organotropism,” Molecular Cancer 24, no. 1 (2025): 72.

[53] X. Zhang, P. Xie, K. Zhang, and W. Zhang, “Circulating Tumour Cell Isolation, Analysis and Clinical Application,” Cellular Oncology 46, no. 3 (2023): 533–544.

[54] X. Zhong, H. Zhang, Y. Zhu, et al., “Circulating Tumor Cells in Cancer Patients: Developments and Clinical Applications for Immunotherapy,” Molecular Cancer 19, no. 1 (2020): 15.

[55] S. Sharma, R. Zhuang, M. Long, et al., “Circulating Tumor Cell Isolation, Culture, and Downstream Molecular Analysis,” Biotechnology Advances 36, no. 4 (2018): 1063–1078.

[56] D. Gao, I. Vela, A. Sboner, et al., “Organoid Cultures Derived From Patients With Advanced Prostate Cancer,” Cell 159, no. 1 (2014): 176–187.

[57] T. Ebisudani, J. Hamamoto, K. Togasaki, et al., “Genotype-Phenotype Mapping of a Patient-Derived Lung Cancer Organoid Biobank Identifies NKX2-1-Defined Wnt Dependency in Lung Adenocarcinoma,” Cell Reports 42, no. 3 (2023): 112212.

[58] F. Grillet, E. Bayet, O. Villeronce, et al., “Circulating Tumour Cells From Patients With Colorectal Cancer Have Cancer Stem Cell Hallmarks in Ex Vivo Culture,” Gut 66, no. 10 (2017): 1802–1810.

[59] D. Brungs, E. Minaei, A. K. Piper, et al., “Establishment of Novel Long-Term Cultures From EpCAM Positive and Negative Circulating Tumour Cells From Patients With Metastatic Gastroesophageal Cancer,” Scientific Reports 10, no. 1 (2020): 539.

[60] T. Rossi, M. Valgiusti, M. Puccetti, et al., “Gastroesophageal Circulating Tumor Cell Crosstalk With Peripheral Immune System Guides CTC Survival and Proliferation,” Cell Death & Disease 16, no. 1 (2025): 223.

[61] J. C. Fischer, D. Niederacher, S. A. Topp, et al., “Diagnostic Leukapheresis Enables Reliable Detection of Circulating Tumor Cells of Nonmetastatic Cancer Patients,” Proceedings of the National Academy of Sciences 110, no. 41 (2013): 16580–16585.

[62] N. H. Stoecklein, G. Fluegen, R. Guglielmi, et al., “Ultra-Sensitive CTC-Based Liquid Biopsy for Pancreatic Cancer Enabled by Large Blood Volume Analysis,” Molecular Cancer 22, no. 1 (2023): 181.

[63] L. Mout, L. F. van Dessel, J. Kraan, et al., “Generating Human Prostate Cancer Organoids From Leukapheresis Enriched Circulating Tumour Cells,” European Journal of Cancer 150 (2021): 179–189.

[64] R. Würth, E. Donato, L. L. Michel, et al., “Circulating Tumor Cell Plasticity Determines Breast Cancer Therapy Resistance via Neuregulin 1-HER3 Signaling,” Nature Cancer 6, no. 1 (2025): 67–85.

[65] Y. H. Wu, Y. P. Hung, N. C. Chiu, et al., “Correlation Between Drug Sensitivity Profiles of Circulating Tumour Cell-Derived Organoids and Clinical Treatment Response in Patients With Pancreatic Ductal Adenocarcinoma,” European Journal of Cancer 166 (2022): 208–218.

[66] K. C. Lin, L. L. Ting, C. L. Chang, et al., “Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients With Head and Neck Cancer,” Cancers 13, no. 23 (2021): 6076.

[67] H. L. Lee, J. F. Chiou, P. Y. Wang, et al., “Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells From Patients With Small Cell Lung Cancer,” Cancers 12, no. 11 (2020): 3394.

[68] Y. H. Wu, H. Chao, C. L. Chiang, et al., “Personalized Cancer Avatars for Patients With Thymic Malignancies: A Pilot Study With Circulating Tumor Cell-Derived Organoids,” Thoracic Cancer 14, no. 25 (2023): 2591–2600.

[69] S. Nagrath, L. V. Sequist, S. Maheswaran, et al., “Isolation of Rare Circulating Tumour Cells in Cancer Patients by Microchip Technology,” Nature 450, no. 7173 (2007): 1235–1239.

[70] Z. Wang, W. Wu, Z. Wang, et al., “Ex Vivo Expansion of Circulating Lung Tumor Cells Based on One-Step Microfluidics-Based Immunomagnetic Isolation,” Analyst 141, no. 12 (2016): 3621–3625.

[71] X. Hong, W. Roh, R. J. Sullivan, et al., “The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis,” Cancer Discovery 11, no. 3 (2021): 678–695.

[72] M. Yu, A. Bardia, N. Aceto, et al., “Ex Vivo Culture of Circulating Breast Tumor Cells for Individualized Testing of Drug Susceptibility,” Science 345, no. 6193 (2014): 216–220.

[73] R. Klotz, A. Thomas, T. Teng, et al., “Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers,” Cancer Discovery 10, no. 1 (2020): 86–103.

[74] R. Y. Ebright, M. A. Zachariah, D. S. Micalizzi, et al., “HIF1A Signaling Selectively Supports Proliferation of Breast Cancer in the Brain,” Nature Communications 11, no. 1 (2020): 6311.

[75] R. Y. Ebright, S. Lee, B. S. Wittner, et al., “Deregulation of Ribosomal Protein Expression and Translation Promotes Breast Cancer Metastasis,” Science 367, no. 6485 (2020): 1468–1473.

[76] N. V. Jordan, A. Bardia, B. S. Wittner, et al., “HER2 Expression Identifies Dynamic Functional States Within Circulating Breast Cancer Cells,” Nature 537, no. 7618 (2016): 102–106.

[77] Y. Zheng, D. T. Miyamoto, B. S. Wittner, et al., “Expression of β-Globin by Cancer Cells Promotes Cell Survival During Blood-Borne Dissemination,” Nature Communications 8 (2017): 14344.

[78] L. Ju, J. Yang, C. Zhai, S. Chai, Z. Dong, and M. Li, “Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients,” Frontiers in Oncology 11 (2021): 683318.

[79] B. L. Khoo, G. Grenci, Y. B. Lim, S. C. Lee, J. Han, and C. T. Lim, “Expansion of Patient-Derived Circulating Tumor Cells From Liquid Biopsies Using a CTC Microfluidic Culture Device,” Nature Protocols 13, no. 1 (2018): 34–58.

[80] Y. Xiang, H. Zhang, H. Lu, et al., “Bioorthogonal Microbubbles With Antifouling Nanofilm for Instant and Suspended Enrichment of Circulating Tumor Cells,” ACS Nano 17, no. 10 (2023): 9633–9646.

[81] T. J. Li, T. W. Lin, S. P. Wu, et al., “Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound,” Molecules 26, no. 19 (2021): 6018.

[82] M. L. De Angelis, F. Francescangeli, C. Nicolazzo, et al., “An Organoid Model of Colorectal Circulating Tumor Cells With Stem Cell Features, Hybrid EMT State and Distinctive Therapy Response Profile,” Journal of Experimental & Clinical Cancer Research: CR 41, no. 1 (2022): 86.

[83] L. Zhang, S. Mo, X. Hu, et al., “Establishment and Identification of Organoids From Human Circulating Colorectal Cancer Cells,” Clinical and Translational Medicine 10, no. 8 (2020): e247.

[84] B. Hong, X. Zhang, X. Du, et al., “Exploring the Potential Driver Gene Mutations That Promote Renal Cancer Cell Metastasis and Implantation Based on Circulating Tumor Cells Culture,” Diagnostics 13, no. 11 (2023): 1855.

[85] J. Xiao, U. Sharma, A. Arab, et al., “Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and COP1 in Metastasis,” Cancers 15, no. 6 (2023): 1831.

[86] J. Xiao, J. R. McGill, K. Stanton, et al., “Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis,” Cancers 12, no. 10 (2020): 2784.

[87] T. De, S. Goyal, G. Balachander, et al., “A Novel Ex Vivo System Using 3D Polymer Scaffold to Culture Circulating Tumor Cells From Breast Cancer Patients Exhibits Dynamic E-M Phenotypes,” Journal of Clinical Medicine 8, no. 9 (2019): 1473.

[88] C. Mihalcioiu, J. Li, D. Badescu, et al., “Improved Platform for Breast Cancer Circulating Tumor Cell Enrichment and Characterization With Next-Generation Sequencing Technology,” American Journal of Cancer Research 13, no. 1 (2023): 25–44.

[89] S. Hassan, T. Blick, E. W. Thompson, and E. D. Williams, “Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells From Prostate Cancer Patient-Derived Xenograft Models,” Cancers 13, no. 11 (2021): 2750.

[90] Z. Zhang, H. Shiratsuchi, J. Lin, et al., “Expansion of CTCs From Early Stage Lung Cancer Patients Using a Microfluidic Co-Culture Model,” Oncotarget 5, no. 23 (2014): 12383–12397.

[91] S. Kim, S. Min, Y. S. Choi, et al., “Tissue Extracellular Matrix Hydrogels as Alternatives to Matrigel for Culturing Gastrointestinal Organoids,” Nature Communications 13, no. 1 (2022): 1692.

[92] N. Carmona-Ule, M. González-Conde, C. Abuín, et al., “Short-Term Ex Vivo Culture of CTCs From Advance Breast Cancer Patients: Clinical Implications,” Cancers 13, no. 11 (2021): 2668.

[93] X. Luo, X. Zhao, C. Cheng, N. Li, Y. Liu, and Y. Cao, “The Implications of Signaling Lipids in Cancer Metastasis,” Experimental & Molecular Medicine 50, no. 9 (2018): 1–10.

[94] M. Nomura, Y. Miyake, A. Inoue, et al., “Single-Cell Analysis of Circulating Tumor Cells From Patients With Colorectal Cancer Captured With a Dielectrophoresis-Based Micropore System,” Biomedicines 11, no. 1 (2023): 203.

[95] M. Yu, A. Bardia, B. S. Wittner, et al., “Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition,” Science 339, no. 6119 (2013): 580–584.

[96] M. C. Scheidmann, F. Castro-Giner, K. Strittmatter, et al., “An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression,” Cancer Research 82, no. 4 (2022): 681–694.

[97] D. S. Potter, M. Galvin, S. Brown, et al., “Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC,” Molecular Cancer Therapeutics 15, no. 6 (2016): 1248–1260.

[98] C. A. Stewart, C. M. Gay, Y. Xi, et al., “Single-Cell Analyses Reveal Increased Intratumoral Heterogeneity After the Onset of Therapy Resistance in Small-Cell Lung Cancer,” Nature Cancer 1 (2020): 423–436.

[99] T. Tayoun, V. Faugeroux, M. Oulhen, et al., “Targeting Genome Integrity Dysfunctions Impedes Metastatic Potency in Non-Small Cell Lung Cancer Circulating Tumor Cell-Derived Explants,” JCI Insight 7, no. 11 (2022), https://doi.org/10.1172/jci.insight.155804.

[100] A. Fumagalli, K. C. Oost, L. Kester, et al., “Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer,” Cell Stem Cell 26, no. 4 (2020): 569–578.e7.

[101] S. Maheswaran and D. A. Haber, “Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy,” Cancer Research 75, no. 12 (2015): 2411–2415.

[102] M. Yu, S. Stott, M. Toner, S. Maheswaran, and D. A. Haber, “Circulating Tumor Cells: Approaches to Isolation and Characterization,” Journal of Cell Biology 192, no. 3 (2011): 373–382.

[103] E. A. Kwizera, W. Ou, S. Lee, et al., “Greatly Enhanced CTC Culture Enabled by Capturing CTC Heterogeneity Using a PEGylated PDMS-Titanium-Gold Electromicrofluidic Device With Glutathione-Controlled Gentle Cell Release,” ACS Nano 16, no. 7 (2022): 11374–11391.

[104] H. Clevers, “Modeling Development and Disease With Organoids,” Cell 165, no. 7 (2016): 1586–1597.

[105] M. L. Espejo-Cruz, S. González-Rubio, J. J. Espejo, et al., “Enumeration and Characterization of Circulating Tumor Cells in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization,” International Journal of Molecular Sciences 24, no. 3 (2023): 2558.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).